% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:182490,
      author       = {K. Hemminki$^*$ and A. Försti$^*$ and O. Hemminki and V.
                      Liska and A. Hemminki},
      title        = {{L}ong-term survival trends for primary liver and
                      pancreatic cancers in the {N}ordic countries.},
      journal      = {JHEP reports},
      volume       = {4},
      number       = {12},
      issn         = {2589-5559},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2022-02685},
      pages        = {100602},
      year         = {2022},
      note         = {#EA:C020#},
      abstract     = {Liver cancer (LC) and pancreatic cancer (PC) are often
                      diagnosed at an advanced stage resulting in high mortality.
                      High-quality survival data are rarely available for trend
                      analyses over a long period.The Danish, Finnish, Norwegian,
                      and Swedish cancer data were accessed at the NORDCAN
                      database. We analysed relative 1- and 5-year survival trends
                      in LC and PC between years 1970 and 2019.Relative 1-year
                      survival in LC for Nordic men and women was about $10\%$ in
                      the period between 1970 and 1974, and it increased
                      moderately by year 2000 and steeply thereafter, eventually
                      reaching $40-50\%.$ The patterns in 5-year survival were
                      similar, but after the year 2000, survival in Norway and
                      Sweden increased steeply to $23\%,$ whereas survival in
                      Denmark and Finland lagged behind, reaching $10\%$ to
                      $15\%.$ The patterns for PC also showed rapid improvement
                      after the year 2000, with 1-year survival reaching $30\%$ to
                      $40\%$ and 5-year survival reaching $10\%$ for Finland and
                      $15\%$ for Norway and Sweden. Survival was best for patients
                      diagnosed before age 50 years, and it was worst for older
                      patients. For both cancers the difference between 1- and
                      5-year survival increased with time.Survival in LC and PC
                      improved first modestly and then steeply over the 50-year
                      period covered. The increase in 5-year survival was less
                      than that of 1-year survival. The survival gains were most
                      likely the result of earlier diagnosis, improved treatment,
                      and better organised supportive care. The challenges are to
                      keep up these positive trends, to extend survival benefits
                      past Year 1, and to obtain similar results in elderly
                      patients. Primary prevention through avoidance of risk
                      factors would reduce case numbers.Liver and pancreatic
                      cancers are among the most lethal of all cancers. In 50
                      years, survival in these cancers has slowly improved, and in
                      the past 20 years, the development has been increasingly
                      favourable. Widespread adoption of healthy lifestyles will
                      be key to reducing the risk of these cancers.},
      keywords     = {CI5, Cancer Incidence in Five Continents (Other) / DK,
                      Denmark (Other) / FI, Finland (Other) / Hepatocellular
                      carcinoma (Other) / IARC, International Agency for Research
                      on Cancer (Other) / ICD, International Classification of
                      Diseases (Other) / ICSS, International Cancer Survival
                      Standard (Other) / IPMN, intraductal papillary mucinous
                      neoplasm (Other) / LC, liver cancer (Other) / Mortality
                      (Other) / NO, Norway (Other) / PAF, population attributable
                      fraction (Other) / PC, pancreatic cancer (Other) / Relative
                      survival (Other) / Risk factors (Other) / SE, Sweden (Other)
                      / Treatment (Other)},
      cin          = {C020 / B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36352895},
      pmc          = {pmc:PMC9638835},
      doi          = {10.1016/j.jhepr.2022.100602},
      url          = {https://inrepo02.dkfz.de/record/182490},
}